Oakcliff Capital Partners’s GoodRx Holdings GDRX Stock Holding History

Oakcliff Capital Partners’s Portfolio GDRX Stock Details GDRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-296,233	Closed	-$9.68M	–	11
2021 Q4	$9.68M	Buy	+296,233	New	+$11.9M	4.42%	10

Other funds holding GDRX

FPM

Francisco Partners Management San Francisco, California $292M AUM 34.13% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LSCM

Light Street Capital Management Palo Alto, California $534M AUM 59.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

SLG

Silver Lake Group Menlo Park, California $3.68B AUM 7.22% 1-Year Est. Return

TCMX

Technology Crossover Management X Menlo Park, California $781M AUM 18.39% 1-Year Est. Return

DIG

Dragoneer Investment Group San Francisco, California $3B AUM 6.95% 1-Year Est. Return

RRCP

Rip Road Capital Partners Boston, Massachusetts $62.5M AUM 1.22% 1-Year Est. Return

LOAMS

Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return

Oakcliff Capital Partners's GDRX Position: Q1 2022 in Review

Oakcliff Capital Partners sold out of GoodRx Holdings (GDRX) in Q1 2022, closing a stake of 296,233 shares — an estimated $9.68M sold.

Oakcliff Capital Partners first reported a position in GDRX in Q4 2021 and held it in 1 quarter. The position peaked at $9.68M in Q4 2021. 167 funds tracked by Wall St. Rank hold GDRX as of Q1 2022.

Oakcliff Capital Partners reported no remaining GoodRx Holdings position as of Q1 2022 after selling out during the quarter.
Oakcliff Capital Partners sold 296,233 GoodRx Holdings shares in Q1 2022, an estimated $9.68M.
Oakcliff Capital Partners first reported a position in GoodRx Holdings in Q4 2021 and held it in 1 quarter.
Oakcliff Capital Partners's GoodRx Holdings position peaked at $9.68M in Q4 2021.
167 funds tracked by Wall St. Rank held GoodRx Holdings as of Q1 2022.

Based on Oakcliff Capital Partners's 13F filing for Q1 2022, filed 16 May 2022.